RoslinCT has entered into a strategic partnership with Gamida Cell to manufacture their FDA-Approved Cell Therapy Omisirge®, a commercial product for the treatment of hematologic malignancies. Read the full press release here: https://t.co/yfLenqhOGI

Exploring treatment options in allo-HSCT? Join us on February 12, 1:30-2:30pm HST in PIT Room 3 as Dr. Stephanie Tsai and Dr. Ronit Simantov present “Options When a Matched Allo-HSCT is Not Available”. #Tandem25 WARNING: INFUSION REACTIONS, GRAFT VERSUS HOST DISEASE,

Aloha! We're excited to be in Hawaii for #Tandem25! Stop by Gamida Cell Booth 101 to chat with our team and discover the benefits of Omisirge® (omidubicel-onlv). WARNING: INFUSION REACTIONS, GRAFT VERSUS HOST DISEASE, ENGRAFTMENT SYNDROME, and GRAFT FAILURE. See full Prescribing

Our team is arriving in San Diego! Visit our booths (2247 + 2346) at #ASH24 to learn more about Omisirge® (omidubicel-onlv). WARNING: INFUSION REACTIONS, GRAFT VERSUS HOST DISEASE, ENGRAFTMENT SYNDROME, and GRAFT FAILURE. See full Prescribing Information, including Boxed

Looking forward to the ASH Annual Meeting? #ASH24 Join us on December 8, 8-9am PT as Dr. Ronit Simantov presents “Options When a Matched Allo-HSCT is Not Available”. WARNING: INFUSION REACTIONS, GRAFT VERSUS HOST DISEASE, ENGRAFTMENT SYNDROME, and GRAFT FAILURE. See Full

We’re excited to welcome APHEXDA® (motixafortide) into the Gamida Cell portfolio, strengthening our commitment to innovative therapies. Together with OMISIRGE® (omidubicel-onlv), we’re advancing options for patients in need of stem cell transplants. #GamidaCell #APHEXDA

Mark your calendars! See what’s new with Gamida at this year’s NMDP One Forum and ASTCT Toxicities Conference.

Two poster presentations highlighted Gamida Cell research at #Tandem24, hosted by @ASTCT & @CIBMTR. Learn more in our press release: https://t.co/dBlfDbX8AX #celltherapy #ASTCT #CIBMTR

Note: Gamida Cell is not responsible for and does not endorse the content found within third party websites.

Today is #NationalDonorDay, a day focused on the life-saving benefits of organ, tissue, marrow, platelet & blood donations. Learn more about donating blood stem cells and cord blood @nmdp_org: https://t.co/r3bZDRq14I #NMDP

@BioNJ_Org Note: Gamida Cell is not responsible for and does not endorse the content found within third party websites.

@BioNJ_Org We are honored to be recognized alongside other companies at the forefront of innovation in biopharma. See the other honorees and learn more about the award at: https://t.co/57BXXiQNVv.

Thank you to @BioNJ_Org for honoring us with a 2024 Innovator Award! This award recognizes BioNJ member companies that received a new FDA drug approval in 2023. #BioNJDinner2024 #InnovationCelebration

Gamida Cell is proud to have talented women at the forefront of therapeutic advances in biopharma!

We celebrate @UN’s International Day of Women & Girls in Science (#IDWGS) & recognize the contributions of #WomeninScience at Gamida Cell. We asked several inspiring team members about their journey to STEM & their advice for others pursuing biopharma careers.

Today marks the celebration of Family Day in Israel, a day that recognizes the diverse dynamics, roles and structures of family units and celebrates the differences that make each one special. Happy Family Day! #FamilyDay #IsraelFamilyDay

Note: Gamida Cell is not responsible for and does not endorse the content found within third party websites.

Today is #WorldCancerDay & the last year of the Union for International Cancer Control (@uicc) 2022-2024 #CloseTheCareGap campaign. Gamida Cell recognizes the importance of helping to increase equitable access to cancer care. Learn more: https://t.co/Z15hXyZVxm

Note: Gamida Cell is not responsible for and does not endorse the content found within third party websites #NKcell #naturalkillercell #celltherapy

Gamida Cell was featured in a recent @DrugDiscovNews article about the promise of the company's proprietary NAM technology and how it’s being applied to investigational NK cell therapy candidate GDA-201. To read the full article, visit: